Characteristics and outcomes of SARS-CoV-2 infection in Victorian children at a tertiary paediatric hospital

Shidan Tosif, Laila F Ibrahim, Rebecca Hughes, Daryl R Cheng, Danielle Wurzel, Isabella Overmars, Andrew C Steer, Penelope A Bryant, Trevor Duke, Stuart Lewena, Franz E Babl, Sarah McNab and Nigel Crawford

1Department of Paediatrics, University of Melbourne, 2Infection and Immunity, 3Emergency Research, Clinical Sciences, Murdoch Children’s Research Institute, 4Departments of General Medicine, 5Department of Respiratory Medicine, 6Infectious Diseases Unit, Department of General Medicine, 7Intensive Care Unit, 8Emergency Department, The Royal Children’s Hospital and 9Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia

Aim: Victoria experienced two ‘waves’ of COVID-19 between March and September 2020 and more cases than any other jurisdiction in Australia. Although world-wide reports of COVID-19 reflect that children are less likely to experience severe disease compared with adults, hospitalisations and deaths have been reported. We report testing and outcomes of children with SARS-CoV-2 infection presenting to a tertiary paediatric hospital in Melbourne.

Methods: We conducted a prospective cohort study at The Royal Children’s Hospital (RCH), including all children and adolescents (aged 0–18 years) who presented and were tested for SARS-CoV-2 over a 6-month period, between 21 March 2020, up to the 21 September 2020. Detailed epidemiological and clinical data were recorded.

Results: A total of 19 708 tests for SARS-CoV-2 were performed in 14 419 patients. One hundred and eighty patients tested positive for SARS-CoV-2 (1.2%). 110 (61%) were symptomatic, 60 (33%) were asymptomatic and 10 (6%) were pre-symptomatic. Close contacts of a positive case were associated with a higher risk of a testing positive for SARS-CoV-2 (120/2027 (6%) vs. 60/14589 (0.4%), RD 5.5 (95% CI 4.5 to 6.5), P < 0.001). Eighteen (10%) SARS-CoV-2-positive patients were admitted to hospital with one patient requiring intensive care. All patients recovered fully with no deaths.

Conclusion: In Victorian children presenting to a tertiary hospital, SARS-CoV-2 infection caused predominantly mild or asymptomatic infection, with most children not requiring hospitalisation.

Key words: COVID-19; general paediatrics; infectious disease.
than 1 month, male or with pre-existing medical conditions.\textsuperscript{14,15} Children with severe disease may present with a relatively brief illness duration and atypical symptoms.\textsuperscript{15} Up until April 20, 2021, there had been 297 cumulative child deaths in the USA representing 0.06\% of total deaths.\textsuperscript{16} Deaths have been reported in Brazil\textsuperscript{17} and Italy,\textsuperscript{18} mostly in children with comorbidities.

More information is needed to describe the presentation, clinical course and outcomes of COVID-19 in children, in particular amongst Australian children. Here we report testing and outcomes of children SARS-CoV-2 in children presenting to a tertiary paediatric hospital in Victoria.

\textbf{Methods}

\textbf{Study design and participants}

We conducted a prospective cohort study at The Royal Children’s Hospital (RCH), a large tertiary paediatric hospital in Melbourne, Australia. We used similar methodology to a previously published paper from the first month of the pandemic.\textsuperscript{14} We included all paediatric patients (aged 0–18 years) who were tested for SARS-CoV-2 from the first positive confirmed case at RCH (21 March 2020), for 6 months until 21 September 2020, corresponding with the epidemiologic peaks in Melbourne.\textsuperscript{19} Testing sites included patients presenting to a dedicated walk-in testing clinic (Respiratory Infection Clinic (RIC)), Emergency Department (ED), Hospital in the Home and inpatient wards. We also included patients who were admitted to RCH (> 4 h in hospital), those treated for COVID-19 who tested positive at an external location or by an RCH outbreak investigation outreach team. Admitted patients were followed up and outcomes were collected at discharge and from follow-up at a dedicated COVID-19 clinic. Ethics approval was obtained from the institutional human research and ethics committee (RCH HREC 62062).

\textbf{Procedures}

At the RCH since early March, any patient presenting to the ED or RIC underwent COVID-19 screening questions according to Victorian Department of Health and Human Services guidelines.\textsuperscript{19} Patients who attended the RIC were asked to complete a questionnaire to report epidemiological risk factors, symptoms and comorbidities. The decision to admit or discharge a patient was made on clinical grounds.

Combined nasopharyngeal and oropharyngeal or deep nasal and oropharyngeal flocked swabs with or without viral transport medium (as available) were processed at the RCH molecular microbiology laboratory. SARS-CoV-2 nucleic acid detection was performed using LightMix Modular SARS and Wuhan CoV E-gene assay (TIB Molbiol, Berlin, Germany) and the AusDiagnostics Respiratory Pathogens 16-well assay (Auds diagnostics, Mascot, Australia).

Demographic data, presenting symptoms and history, risk factors, underlying comorbidities, examination findings, laboratory testing and imaging, were obtained from the electronic medical records. Outcomes from hospital admission, or dedicated COVID-19 follow-up clinic, if required, were included. Each record was reviewed for all SARS-CoV-2-positive patients, whilst a summary extraction was performed for SARS-CoV-2-negative patients. These data were entered into a Research Electronic Data Capture (REDCap) database.\textsuperscript{20}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{Fig1.pdf}
\caption{Number of SARS-CoV-2 tests and SARS-CoV-2-positive cases by month. \textsuperscript{[s]} SARS-CoV-2 tested and [ ] SARS-CoV-2 positive.}
\end{figure}
COVID-19 in children

S Tosif et al.

Statistical analysis

We presented continuous variables as mean (SD) and categorical variables as numbers (%). We compared means of continuous variables between groups using independent group t tests when values were normally distributed; otherwise, we used the Mann–Whitney U test. We compared proportions for categorical variables between groups using $\chi^2$. We judged a two-sided $\alpha$ less than 0.05 statistically significant. All data analyses were done with Stata IC version 15.1 (StataCorp, College Station, TX, USA).

Results

Over a 6-month period from 21 March 2020 to 21 September 2020, 19 708 tests for SARS-CoV-2 were performed in 14 419 patients. A total of 14 419 (73%) patients were tested once, 3098 (16%) patients were tested twice, and 2212 (11%) were tested 3 or more times. The number of tests performed and positive cases both peaked in July (Fig. 1). Stratified by age groups, 2051 (14%) were less than 1 year, 7903 (55%) were 1–5 years, 2608 (18%) were 5–10 years, 1857 (13%) were more than 10 years (Table 1). Totally 2574 (18%) of 14 419 tests were in hospitalised patients.

SARS-CoV-2-positive patients

One hundred and eighty patients tested positive for SARS-CoV-2 (see Table 1). The location of testing for positive results was: RIC ($n = 121$, 67%), ED ($n = 39$, 22%), home through the Hospital-in-the-Home service ($n = 10$, 6%), hospital inpatient wards ($n = 4$, 2%), community sites through outreach testing ($n = 3$, 2%) and other hospitals and other sites within RCH ($n = 3$, 2%). With regards to epidemiological risk factors, there were 120 (67%) of 180 positive patients with a history of close contact, 86 (72%) of whom were through household contact and 5 (3%) had a history of recent overseas travel.

At the time of testing positive, 60 (33%) of 180 patients were asymptomatic. Ten (6%) were pre-symptomatic and subsequently developed symptoms. The median time to developing symptoms for these pre-symptomatic patients was 2 days (range 2–11 days). In the 14 days prior to testing positive, there were 16 (9%) of 180 patients who tested negative.

Most of the 180 patients with COVID-19 had either fever ($n = 47$, 26%) or respiratory tract symptoms ($n = 102$, 56%). Headache was reported by 21 (12%) patients. Comorbidities were present in 25 (14%) of positive patients: asthma ($n = 9$), heart disease ($n = 6$), prematurity ($n = 2$), diabetes mellitus ($n = 2$), immunosuppressed ($n = 5$) and developmental delay ($n = 1$).

Hospitalised SARS-CoV-2-positive patients

Eighteen (10%) SARS-CoV-2-positive patients were admitted to hospital and median age was 1.8 years (IQR 4.8 months to 10 years). Of these, four were observed in ED short stay (between 5 and 10 h), one was admitted for observations at home under HITH, nine were admitted to the hospital wards and one patient was transferred directly to the paediatric intensive care unit (PICU) from a different hospital. The remaining three were inpatients who were admitted for non-COVID-19 reasons and subsequently tested positive whilst

Table 1  Epidemiological and clinical features of children stratified by COVID-19 status

| No. (%) | Total | SARS-CoV-2 positive | SARS-CoV-2 negative | Risk or mean difference (95% CI) | P values |
|---------|-------|---------------------|---------------------|---------------------------------|----------|
| **Demographics** |       |                     |                     |                                 |          |
| Total patients ($n$) | 14 419 | 180 [1]             | 14 239 [99]         |                                 |          |
| Female | 6651 (46) | 82 (46)             | 6569 (46)           | -0.00 (–0.1 to 0.1)             | 0.88     |
| Age less than 1 year | 2051 (14) | 31 (17)             | 2020 (14)           | 0.02 (–0.0 to 0.1)              | 0.24     |
| Age 1 to 5 years | 7903 (55) | 89 (49)             | 7814 (55)           | -0.04 (–0.1 to 0.0)             | 0.22     |
| Age 6 to 10 years | 2608 (18) | 29 (16)             | 2579 (18)           | -0.01 (–0.1 to 0.0)             | 0.51     |
| Age more than 10 years | 1857 (13) | 31 (17)             | 1826 (13)           | 0.03 (–0.0 to 0.1)              | 0.12     |
| Admitted to hospital | 2574 (18) | 18 (10)             | 2559 (17)           | -0.08 (–0.04 to –0.12)          | <0.001   |
| Admitted to Intensive Care | 498 (6) | 2 (1)               | 498 (3)             | -0.02 (–0.04 to –0.01)          | 0.10     |
| Deaths | 5 (<1) | 0                   | 5 (<1)              | -0.00 (–0.00 to –0.00)          | 0.80     |
| Risk factors present at time of test |       |                     |                     |                                 |          |
| Contact with positive case | 2027/16616 (12) | 120 (67)             | 1907/16436 (12)     | 0.55 (0.48 to 0.62)             | <0.001   |
| Shared closed space for ≥2 h | N/A | N/A                 | N/A                 |                                 |          |
| Household member | 86 (48) | 48 (26)             | 38 (23)             | 0.02 (0.00 to 0.05)             | <0.001   |
| Close contact in school/childcare | 24 (13) | 14 (7)              | 10 (6)              | 0.09 (0.00 to 0.18)             | 0.03     |
| Exposure to known outbreak | 1 [1] | 1 [1]               | 0 [0]               | 0.09 (–0.17 to –0.02)           | 0.009    |
| Overseas travel in last 14 days | 43/19657 (<1) | 5 [1]               | 38/19477 (<1)       | 0.18 (0.12 to 0.25)             | <0.001   |
| Symptoms present at time of test |       |                     |                     |                                 |          |
| Fever (37.5°Celsius or more)/ chills | 4855 (30) | 47 (39)             | 4810/16097 (30)     | 0.09 (0.00 to 0.18)             | 0.03     |
| Respiratory symptoms | 10 623 (65) | 101 (56)            | 10 522/16089 (65)   | -0.09 (–0.17 to –0.02)          | 0.009    |
| Asymptomatic | 2450 (15) | 60 (33)             | 2390/16097 (15)     | 0.18 (0.12 to 0.25)             | <0.001   |
hospitalised. One patient was exposed by a confirmed positive parent. Despite comprehensive investigation for two other inpatients, a confirmed exposure source was not identified.

The median length of stay in hospital was 2 days (IQR 1–6 days). The majority of hospitalised patients only required observations ($n = 7$) and hydration support ($n = 2$) or treatment for a comorbid condition ($n = 8$). One patient with congenital cardiac disease required intensive care, for respiratory and inotropic support for 48 h, and received remdesivir, tocilizumab, dexamethasone and intravenous immunoglobulins with a 29-day total length of stay.21

Of the 25 children with comorbidities who tested positive to SARS-CoV-2, eight (32%) of 25 were hospitalised versus 10 (6%) of 155 without comorbidities who were hospitalised (RD 25.5 95% CI 6.9 to 44.4, $P < 0.001$). These comorbidities were: congenital cardiac defect ($n = 2$), immunosuppression/malignancy ($n = 2$), prematurity ($n = 2$), diabetes mellitus ($n = 1$), developmental delay ($n = 1$) and reactive airways ($n = 1$).

### Comparison of SARS-CoV-2-positive patients to SARS-CoV-2-negative patients

With regards to epidemiological risk factors, being a close contact of a positive case was associated with a higher risk of a positive SARS-CoV-2 test ($120/2027$ (6%) close contacts testing positive vs. $60/14589$ (0.4%) non-close contacts testing positive, RD 5.5 (95% CI 4.5 to 6.5), $P < 0.001$). Fever was recorded in a higher proportion of SARS-CoV-2-positive patients but respiratory symptoms were higher in SARS-CoV-2-negative patients. For non-hospitalised patients who attended the RIC (Table 2), there were two distinguishing clinical features, which were headache and fever/chills. Headache was present in 17 (15%) of 116 SARS-CoV-2 patients and 420 (5%) of 8538 non-COVID-19 patients ($P = < 0.001$). Presence of comorbidities was no different between the groups ($18/165$ (11%) vs. $599/8413$ (7%), $P = 0.06$).

### Discussion

Despite a sustained period of SARS-CoV-2 community transmission in Victoria, our description of paediatric cases at a tertiary hospital reveals most children had mild disease and 33% of those who tested positive for SARS-CoV-2 were asymptomatic. Only 1% of children required hospitalisation or intensive care. Children with comorbidities were over-represented amongst the hospitalised patients, although these numbers were small. Of those hospitalised, most received only supportive therapy, and all made a full recovery.

### Table 2

Characteristics of non-hospitalised patients who attended Respiratory Infection Clinic

|                         | Total        | SARS-CoV-2 positive | SARS-CoV-2 negative | Risk or mean difference (95% CI) | $P$ values |
|-------------------------|--------------|---------------------|---------------------|---------------------------------|------------|
| Total patients          | 6736         | 165 (2)             | 6571 (98)           |                                 |            |
| Total tests             | 8708         | 189 (2)             | 8519 (98)           |                                 |            |
| Female                  | 3199 (48)    | 76 (47)             | 3123 (48)           | $-0.01 (-0.1 to 0.1)$            | 0.71       |
| Age less than 1 year    | 467 (7)      | 26 (16)             | 441 (7)             | $0.10 (0.0 to 0.1)$              | <0.001     |
| Age 1 to 5 years        | 7903 (55)    | 84 (51)             | 4079 (62)           | $-0.11 (-0.2 to -0.0)$           | 0.004      |
| Age 6 to 10 years       | 2608 (18)    | 27 (16)             | 1300 (20)           | $-0.03 (-0.1 to 0.0)$            | 0.51       |
| Age more than 10 years  | 779 (12)     | 28 (17)             | 751 (11)            | $0.06 (-0.0 to 0.1)$             | 0.03       |
| Risk factors            |              |                     |                     |                                 |            |
| Close contact           | 1738 (20)    | 113 (68)            | 1625 (19)           | $0.49 (0.4 to 0.56)$             | <0.001     |
| Overseas travel         | 3 (2)        | 14 (0.1)            | 14 (0.1)            | $0.02 (-0.0 to 0.04)$            | <0.001     |
| Symptoms                |              |                     |                     |                                 |            |
| Asymptomatic            | 2450 (28)    | 65 (42)             | 2385 (28)           | $0.14 (0.06 to 0.22)$            | <0.001     |
| Cough                   | 3667 (42)    | 68 (49)             | 3599 (42)           | $0.16 (0.07 to 0.25)$            | <0.001     |
| Runny/stuffy nose       | 4415 (51)    | 68 (44)             | 4347 (51)           | $-0.07 (-0.15 to 0.01)$          | 0.07       |
| Sore throat             | 1439 (16)    | 22 (20)             | 1417 (17)           | $0.31 (-0.04 to 0.11)$           | 0.32       |
| Headache                | 437 (5)      | 17 (15)             | 420 (5)             | $0.06 (0.01 to 0.11)$            | <0.001     |
| Muscle ache             | 131 (11)     | 4 (3)               | 127 (1)             | $0.01 (-0.01 to 0.03)$           | 0.27       |
| Fever or chills         | 1239 (14)    | 45 (39)             | 1194 (14)           | $0.25 (0.16 to 0.34)$            | <0.001     |
| Diarrhoea               | 207 (2)      | 0                   | 207 (2)             | $-0.02 (-0.03 to -0.02)$         | 0.04       |
| Anosmia                 | 25 (1)       | 1 (<1)              | 31 (<1)             | $0.00 (-0.01 to 0.02)$           | 0.25       |
| Comorbidities           |              |                     |                     |                                 |            |
| Any comorbidity         | 617 (7)      | 18 (11)             | 599/8413 (7)        | $0.04 (-0.01 to 0.01)$           | 0.06       |
| Asthma                  | 398 (5)      | 9 (6)               | 389 (5)             | $0.01 (-0.02 to 0.05)$           | 0.36       |
| Immunosuppression/malignancy | 277 (3)    | 3 (2)               | 274 (3)             | $-0.01 (-0.03 to 0.01)$          | 0.31       |
| Prematurity             | 56 (1)       | 1 (1)               | 55 (1)              | $0.01 (-0.01 to 0.02)$           | 0.43       |
| Cardiac                 | 44 (1)       | 4 (2)               | 40 (0.5)            | $0.25 (-0.00 to 0.51)$           | <0.001     |
| Developmental delay/cerebral palsy | 53 (1) | 0                   | 53 (1)              | $-0.00 (-0.01 to 0.01)$          | 0.98       |
Our finding of predominantly mild or asymptomatic infection in children with few hospitalisations is similar to international reports in children. Children with comorbidities and younger children are usually considered at special risk of severe disease from viral lower respiratory tract infections. However, COVID-19 appears to rarely impact younger children, and few infants required hospitalisation or intensive care in this cohort. Hypotheses for this difference in immune response for COVID-19 are evolving and include partial protection from other coronaviruses, which are more common in children, and a protective difference in innate response of children compared with adults.

Symptom profiles did not distinguish COVID-19 from other infections. Identifying differences in disease profile, clinical severity and transmission will be important with emerging variants of concern emerge such as Delta. Asymptomatic infection was identified in 33% of patients. The true burden of asymptomatic infection in children and its significance with respect to onward transmission is not known. The lack of unique clinical features and high proportion of asymptomatic patients underscores the importance of testing to identify SARS-CoV-2 infection. In Victoria, contact tracing and mandatory testing of asymptomatic close contacts is likely to have identified more asymptomatic cases than in settings where testing is directed to more unwell or hospitalised patients. A study from South Korea where a large-scale, aggressive contact tracing and testing programme was used identified that 22% (20/91) of infected children were asymptomatic. Further information from contact tracing and household transmission studies are needed to determine the frequency and significance of asymptomatic childhood infection.

Victoria has had a higher proportion of positive SARS-CoV-2 cases in children and adolescence (16%), compared to other countries and cohorts, which range 0.8–2.2%. This may reflect the aggressive suppression strategy with associated widespread testing, including school and childcare outbreaks, as well as a number of asymptomatic testing campaigns. Approximately 2.5 million tests were conducted between March and September 2020, with a test positive rate of 0.8% in Victoria, compared with states in the USA experiencing test positive rates of between 3.6% and 17.8% at the height of COVID19 pandemic.

Whilst SARS-CoV-2 in children generally causes mild disease, the infection is associated with complications. There is increasing recognition of a Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS also known as MIS-C) with potentially life threatening and serious effects. To date, reports of PIMS-TS have occurred from higher SARS-CoV-2 incidence settings. This report has some limitations. Patients at RCH are seen up to age 18 years; there was likely a referral bias towards younger patients based on patients less than 5 years being directed to RCH for SARS-CoV-2 testing. Whilst the report was based on some manual data extraction, we optimised data collection by piloting a standardised electronic data form using trained abstractors and auditing the data extraction.

**Conclusion**

SARS-CoV-2 infection caused predominantly mild or asymptomatic infection, with most children not requiring hospitalisation. A higher proportion of children with comorbidities were admitted to hospital. Further information is needed regarding long-term impact from SARS-CoV-2 in children and differences in transmission and sequelae from emerging variants of concern.

**References**

1. World Health Organisation. WHO Coronavirus Disease (COVID-19) Dashboard 2020. Available from: https://covid19.who.int/.
2. Government of Canada. Coronavirus disease 2019 (COVID-19): epidemiology update. Available from: https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html.
3. European Centre for Disease Prevention and Control. COVID-19 in children and the role of school settings in COVID-19 transmission. Stockholm, 2020.
4. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41:145–51.
5. Centre for Disease Control and Prevention. COVID Data Tracker 2020. Available from: https://covid.cdc.gov/covid-data-tracker/
6. Jason Thompson RM, Stevenson M, Blakely T. Emerging from Lockdown: Modelling, Outputs and Assumptions. Department of Health and Human Services: Victoria; 2020.
7. Australian Government Department of Health. Coronavirus (COVID-19) current situation and case numbers Australia: Australian Government; 2020. Available from: https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-current-situation-and-case-numbers[accessed Nov 2020].
8. Shekerdemian LS, Mahmood NR, Wolfe KK et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr. 2020; 174: 668–73.
9. Raba AA, Abobaker A, Egenaida IS, Daudu A. Novel coronavirus infection (COVID-19) in children younger than one year: A systematic review of symptoms, management and outcomes. Acta Paediatr. 2020; 109: 1948–55.
10. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020; 109: 1088–95.
11. Tagarro A, Epalza C, Santos M, Sanz-Santaeuemia FJ, Otheo E, Moraleda C, et al. Screening and Severity of Coronavirus Disease 2019 (COVID-19) in Children in Madrid, Spain. JAMA Pediatr. 2020; e201346.
12. Dong Y, Mo X, Hu Y et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020; 145: e20200702.
13. Liguori I, Pilotto C, Bonanni M et al. SARS-COV-2 infection in children and newborns: A systematic review. Eur. J. Pediatr. 2020; 179: 1029–46.
14. Ibrahim LF, Tosif S, McNab S et al. SARS-CoV-2 testing and outcomes in the first 30 days after the first case of COVID-19 at an Australian children's hospital. Emerg. Med. Australas. 2020; 32: 801–8.
15. González-Dambrauskas S, Vásquez-Hoyos P, Camporesi A et al. Pediatric critical care and COVID-19. Pediatrics 2020; 146: e20201766.
16. American Academy of Pediatrics. Children and COVID-19: State Data Report. A joint report from the American Academy of Pediatrics and the Children’s Hospital Association; 2020; Version: 11/19/20.
17. de Siqueira Alves Lopes A, Cristina Fontes Vieira S, Lima Santos Porto R et al. Coronavirus Disease-19 deaths among children and adolescents in an area of Northeast, Brazil: Why so many? Trop. Med. Int. Health 2021; 26: 115.
18. Parri N, Lenge M, Cantoni B et al. COVID-19 in 17 Italian pediatric emergency departments. Pediatrics 2020; 146: e20201235.
19 Department of Health and Human Services State Government of Victoria Australia. Coronavirus disease (COVID-19) 2020. Available from: https://www.dhhs.vic.gov.au/health-services-and-general-practitioners-coronavirus-disease-covid-19.

20 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 2009; 42: 377–81.

21 Licciardi P, Wurzel D, Neeland M, et al. Immune Responses in an Infant with Congenital Heart Disease and Severe COVID-19. Research Square; 2021. https://doi.org/10.21203/rs.3.rs-209429/v1

22 van Woensel JBM, van Aalderen WMC, Kimpen JLL. Viral lower respiratory tract infection in infants and young children. BMJ 2003; 327: 36–40.

23 Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch. Dis. Child. 2020; 106: 429–39.

24 Ng KW, Faulkner N, Cornish GH et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 2020; 370: 1339–43.

25 Weisberg SP, Connors TJ, Zhu Y et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat. Immunol. 2020; 22: 25–31.

26 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239–42.

27 Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA 2020; 323: 1335.

28 A joint report from the American Academy of Pediatrics and the Children’s Hospital Association. Children and COVID-19: State Data Report.

29 Jiang L, Tang K, Levin M et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect. Dis. 2020; 20: e276–e88.

30 Davies P, Evans C, Kanthimathinathan HK et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: A multi-centre observational study. Lancet Child Adolesc. Health 2020; 4: 669–77.

31 Cheung EW, Zachariah P, Gorelik M et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA 2020; 324: 294–6.